Abion Inc
Abion Inc is a South Korean biotechnology company focused on pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of biopharmaceutical products.
Business. Abion Inc is a biotechnology and medical research company listed on the KOSDAQ under the ticker symbol 203400.KQ. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Specific details regarding operating segments and geographic presence are not available. The company is headquartered in South Korea, consistent with its primary listing on the Korean exchange.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Abion Inc is a biotechnology and medical research company listed on the KOSDAQ under the ticker symbol 203400.KQ. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Specific details regarding operating segments and geographic presence are not available. The company is headquartered in South Korea, consistent with its primary listing on the Korean exchange.
Abion Inc maintains a strong liquidity position with KRW 34,369,645,560 in cash and equivalents, representing 42.6% of total assets. The company's debt-to-equity ratio of 0.13 indicates a conservative capital structure, with long-term debt accounting for only 11.2% of total equity. The current ratio of 5.82 suggests robust short-term liquidity, well above the typical threshold for financial stability.
Despite its strong liquidity, Abion Inc reported a net loss of KRW 29,063,465,700 in the latest period, with an operating loss of KRW 21,022,825,400. Return on equity (ROE) and return on assets (ROA) were -42.51% and -36.07%, respectively, indicating significant underperformance relative to industry norms. Gross profit of KRW 311,652,280 was insufficient to offset operating expenses, highlighting challenges in cost management and revenue generation.
The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns suggests a lack of diversification risk. Given the absence of segment-specific data, it is unclear whether the company's operations are concentrated in a single therapeutic area or geographic region.
Looking ahead, the company's growth trajectory is uncertain. No specific revenue growth or decline figures are provided in the outlook, but the significant operating and net losses suggest a challenging path to profitability. The company's capital expenditures were KRW 433,684,360, a small fraction of total assets, indicating limited investment in expansion or R&D.
Risk factors include the company's negative cash flow from operations, which totaled KRW -33,044,797,170, and the need for continued financing to support operations. However, the risk assessment indicates low dilution and liquidity risk, with no immediate filing-based flags detected. The company's low dilution risk is supported by the absence of recent equity issuances or shelf registration activity in the available data.
Recent events include the latest financial filing, which discloses the company's significant losses and liquidity position. No recent earnings call transcripts or material regulatory filings are available in the dataset to provide additional context on strategic direction or operational performance.
- Abion Inc has a strong liquidity position with KRW 34.37 billion in cash and equivalents.
- The company reported a net loss of KRW 29.06 billion, with ROE and ROA of -42.51% and -36.07%, respectively.
- Debt-to-equity ratio of 0.13 indicates a conservative capital structure.
- No immediate liquidity or dilution risks were identified in the risk assessment.
- The company's growth trajectory is unclear due to significant operating and net losses.
- No recent strategic or operational updates were disclosed in the available data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Abion Inc Market data — financials · 2026-05-26